MariTide Phase 2: Amgen reports up to 20% weight loss at one year
100% citation coverage1 peer-reviewed sources
Amgen’s MariTide Phase 2 obesity study reported up to ~20% average weight loss at one year in participants without type 2 diabetes and up to ~17% in those with type 2 diabetes. The plan below focuses only on the trial facts, the placebo comparisons, and the clinical-trial readouts already supported by source material.
Intelligence Snapshot
Executive Summary
MariTide demonstrated up to ~20% average weight loss in people living with obesity without Type 2 diabetes compared with 2.6% in the placebo arm, and up to ~17% average weight loss in people living with obesity with Type 2 diabetes compared with 1.4% in the placebo arm.
Key Insights
-
In the Phase 2 trial, once-monthly maridebart cafraglutide resulted in substantial weight…
In the Phase 2 trial, once-monthly maridebart cafraglutide resulted in substantial weight reduction in participants with obesity with or without type 2 diabetes, with no weight loss plateau observed at 52 weeks.
-
Amgen has initiated multiple Phase 3 trials across cardiovascular, sleep apnea, and…
Amgen has initiated multiple Phase 3 trials across cardiovascular, sleep apnea, and heart-failure populations, with a separate Phase 2 study recruiting in elevated liver fat and obesity or overweight.
Market Impact
| Regulatory | medium |
|---|---|
| Commercial | medium |
| Competitive | high |
| Investment | medium |
Loading intelligence…
Quick Answer
MariTide demonstrated up to ~20% average weight loss in people living with obesity without Type 2 diabetes compared with 2.6% in the placebo arm, and up to ~17% average weight loss in people living with obesity with Type 2 diabetes compared with 1.4% in the placebo arm.
Key Questions
- What is MariTide's dosing schedule?
- How does MariTide compare to placebo in weight loss outcomes?
- What does the Phase 2 trial tell us about MariTide's clinical profile?
- What is the regulatory status of MariTide?
- What is the cost or pricing of MariTide?
Executive Scorecard
Heuristic scores · directional, not investment adviceRegulatory catalyst tracker
Track PDUFA dates, approval milestones, and label updates for MariTide.
Unlock full calendar →Amgen pipeline snapshot
One-screen view of active programs, phases, and recent catalysts from public sources.
Contents10 sections
MariTide Phase 2: Amgen reports up to 20% weight loss at one year
Amgen's MariTide Phase 2 obesity study reported up to ~20% average weight loss at one year in participants without type 2 diabetes and up to ~17% in those with type 2 diabetes, versus placebo rates of 2.6% and 1.4% respectively. MariTide Phase 3 trials are now recruiting across cardiovascular, sleep apnea, and heart-failure populations, with once-monthly maridebart cafraglutide showing substantial weight reduction in participants with obesity with or without type 2 diabetes.
IntelligenceRegulatory Impact
FDA and EMA decisions frame this story. Regulatory relevance is medium for obesity, with MariTide and maridebart cafraglutide most exposed. Track designations, submission types, and label or guidance shifts that could move timelines.
Key Takeaways
- MariTide demonstrated up to ~20% average weight loss in people living with obesity without Type 2 diabetes compared with 2.6% in the placebo arm, and up to ~17% average weight loss in people living with obesity with Type 2 diabetes compared with 1.4% in the placebo arm.
- In the Phase 2 trial, once-monthly maridebart cafraglutide resulted in substantial weight reduction in participants with obesity with or without type 2 diabetes, with no weight loss plateau observed at 52 weeks.
- Amgen has initiated multiple Phase 3 trials across cardiovascular, sleep apnea, and heart-failure populations, with a separate Phase 2 study recruiting in elevated liver fat and obesity or overweight.
IntelligenceCompetitive Intelligence
Competitive pressure is high. Amgen reshape positioning, formulary leverage, and partnership options. Benchmark pipeline differentiation and regional market access assumptions against this development.
Phase 2 efficacy and trial design
Once-monthly maridebart cafraglutide resulted in substantial weight reduction in participants with obesity with or without type 2 diabetes in the Phase 2 study. The trial stratified participants by diabetes status and measured weight loss against placebo controls. MariTide is a monthly or less frequently dosed obesity treatment that demonstrated up to approximately 20% average weight loss without a weight loss plateau.
For participants without Type 2 diabetes, MariTide demonstrated up to approximately 20% average weight loss compared with 2.6% in the placebo arm. Among those with Type 2 diabetes, the drug achieved up to approximately 17% average weight loss compared with 1.4% in the placebo arm. The separation from placebo underscores the drug's activity across both patient populations at the one-year mark.
IntelligenceMarket Signals
Commercial pull is medium and investment relevance medium for obesity. Expect implications for pricing, access, and launch sequencing.
What Phase 3 trials is Amgen conducting for MariTide?
Amgen has advanced MariTide into Phase 3 trials targeting obesity-related comorbidities. A Phase 3 trial is recruiting participants with obstructive sleep apnea not on positive airway pressure therapy, while a separate Phase 3 study is enrolling adults with obstructive sleep apnea on PAP therapy. The company is also evaluating the impact of maridebart cafraglutide on cardiovascular outcomes in participants with atherosclerotic cardiovascular disease and overweight or obesity and testing the drug in heart failure with preserved or mildly reduced ejection fraction and obesity.
Amgen has a Phase 3 trial not yet recruiting to evaluate efficacy and safety of switching from GLP-1 receptor agonists to maridebart cafraglutide in adults with obesity or overweight (MARITIME-SWITCH). The company is also recruiting for a Phase 2 trial evaluating efficacy and safety in adults living with elevated liver fat and obesity or overweight.
IntelligenceStrategic Takeaways
MariTide demonstrated up to ~20% average weight loss in people living with obesity without Type 2 diabetes compared with 2.6% in the placebo arm, and up to ~17% average weight loss in people living with obesity with Type 2 diabetes compared with 1.4% in the placebo arm. In the Phase 2 trial, once-monthly maridebart cafraglutide resulted in substantial weight reduction in participants with obesity with or without type
Trial Snapshot
| Trial | Title | Status | Phase | Sponsor |
|---|---|---|---|---|
| NCT07226765 | Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) Therapy | RECRUITING | PHASE3 | Amgen |
| NCT07037433 | Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity | RECRUITING | PHASE3 | Amgen |
| NCT07037459 | Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity | RECRUITING | PHASE3 | Amgen |
| NCT07225686 | Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy | RECRUITING | PHASE3 | Amgen |
| NCT07575399 | Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH) | NOT_YET_RECRUITING | PHASE3 | Amgen |
IntelligenceEvidence Quality
Grounded in 1 peer-reviewed source.
Competitor Matrix
| Company / Program | Indication | Active trials |
|---|---|---|
| National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | obesity | 3 |
| Chendu DIAO Pharmaceutical Group CO., LTD. | obesity | 1 |
| National Human Genome Research Institute (NHGRI) | obesity | 1 |
| National Heart, Lung, and Blood Institute (NHLBI) | obesity | 1 |
| Eli Lilly and Company | obesity | 1 |
| Shandong Suncadia Medicine Co., Ltd. | obesity | 1 |
Timeline
- Recruiting trial NCT07226765 (PHASE3)
- Recruiting trial NCT07037433 (PHASE3)
- Recruiting trial NCT07037459 (PHASE3)
- Recruiting trial NCT07225686 (PHASE3)
- Not_Yet_Recruiting trial NCT07575399 (PHASE3)
Frequently Asked Questions
What is MariTide's dosing schedule?
MariTide is dosed monthly or less frequently.
How does MariTide compare to placebo in weight loss outcomes?
In people living with obesity without Type 2 diabetes, MariTide achieved up to ~20% average weight loss compared with 2.6% on placebo. In those with Type 2 diabetes, the drug produced up to ~17% average weight loss versus 1.4% on placebo. These differences represent substantial separation from placebo control at one year.
What does the Phase 2 trial tell us about MariTide's clinical profile?
Once-monthly maridebart cafraglutide resulted in substantial weight reduction in participants with obesity with or without type 2 diabetes. The drug demonstrated up to approximately 20% average weight loss without a weight loss plateau at 52 weeks, suggesting sustained efficacy across the study population.
What is the regulatory status of MariTide?
MariTide is currently in Phase 2 and Phase 3 clinical development. The drug has not yet received FDA approval.
What is the cost or pricing of MariTide?
Pricing information for MariTide is not disclosed in the available clinical trial data or regulatory filings reviewed for this article.
Related profiles
Related coverage
Continue Exploring
Jump into the entities behind this story.
Ask AI About obesity
Grounded in NovaPharmaNews intelligence. Pick a prompt to start.
Follow MariTide developments
FDA obesity alerts and MariTide pipeline updates, every Monday.
- Sources analyzed
- 1
- Evidence strength
- 87/100
- Last verified
- Jun 7, 2026
- AI-assisted review
- Yes
- Editorial review
- Dr. Sarah Chen
High source quality · grounded in cited primary and secondary sources.
This article follows our editorial standards. Report a correction via editorial contact.
About the Author
Continue Your Research
Industry Reports & Whitepapers
- Ensuring Compatibility for GLP-1-based Drugs — The rise of GLP-1 agonists like Semaglutide demands innovative ready-to-use cartridges to enhance de…